A large real-world study of nearly 300,000 osteoporosis patients found no increased risk of atypical femur fractures with denosumab compared to bisphosphonates. The findings, presented at the 2026 ...
Adults with osteoporosis prescribed the antiresorptive denosumab were no more likely to sustain an atypical femur fracture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results